FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2924014797> ?p ?o ?g. }

• W2924014797 endingPage "10" @default.
• W2924014797 startingPage "4" @default.
• W2924014797 abstract "Background: Early stage breast cancer can often be cured with surgery alone though there are chances of recurrent disease and decrease in survival. Adjuvant poly-chemotherapy with docetaxel-based regimens can improve both disease-free and overall survival in patients with operable breast cancer.&#x0D; Objective: This study was designed to evaluate the patient profile and current pattern of care with docetaxel based adjuvant regimen in operable breast cancer patients including the treatment outcome from clinical practice.&#x0D; Materials and method: This prospective, observational, non-comparative study planned to enroll newly diagnosed operable breast cancer patients with high risk of recurrence after surgery. Selection of docetaxel-based treatment strategy and dosage of therapy was at the discretion of individual oncologists as per routine clinical practice. Patient data were recorded during inclusion, each cycle of therapy, and follow-up at 1 year (+/- 1 month) after inclusion.&#x0D; Results: Between August 2008 and July 2011 a total of 85 patients with median age of 53 years (23-73 years) were enrolled and 53 (62.4%) patients were postmenopausal. Ductal carcinoma, the most common cancer type,was found in 73 (85.9%) patients. Receptor status was positive for estrogen, progesterone or Her2/neu/erbB2 in 65.9%, 47.1% and 5.8% patients, respectively. Mastectomy either partial or total was performed in 76 (89.4%) patients for the current disease. An average of 8 (range: 2-15) lymph nodes (LN) mostly in axilla were excised in 56 patients and average of 4 (range: 1-11) LN nodes were positive. Sentinel LNs were negative, excised in 4 patients. The mean tumor size was 5.5 cm and most (82.4%) patients were diagnosed at Stage II disease including some at Stage I and III (7.1%, 10.6%). Docetaxel (Taxotere®) was combined with cyclophosphamide alone or in addition with doxorubicin, epirubicin, 5 FU and trastuzumab either in combination or sequential regimen. Taxotere in combination with adriamycin and cyclophosphamide was planned for 63.5% patients. Trastuzumab as sequential therapy could be afforded by 1 patient only. Data regarding radiotherapy or hormone therapy was not recorded. At the end of four cycles, 83.5% of patients were found disease free and 5.9% had loco regional relapse. At 1 year 71 (93.4%) patients were alive, 63 (88.7%) were relapse-free and 8 (11.2%) had loco regional relapse. Nausea, vomiting, diarrhea, alopecia, anemia and neutropenia were most commonly reported adverse events classified as Grade 1 or Grade 2. Grade 3 neutropenia was reported in 5 patients and 2 patients reported grade 4 neutropenia. Grade 3 diarrhea was reported in 1 patient.&#x0D; Conclusion: Docetaxel as adjuvant chemotherapy offered one year survival in 93.4% (71/76) of the patients and 88.7% (63/71 patients) were disease-free. The safety profile of docetaxel based regimens was expected and manageable.&#x0D; Delta Med Col J. Jan 2019 7(1): 4-10" @default.
• W2924014797 created "2019-04-01" @default.
• W2924014797 creator A5000605562 @default.
• W2924014797 creator A5043860820 @default.
• W2924014797 creator A5044433215 @default.
• W2924014797 creator A5051277841 @default.
• W2924014797 creator A5068460437 @default.
• W2924014797 creator A5078578009 @default.
• W2924014797 date "2019-03-19" @default.
• W2924014797 modified "2023-10-18" @default.
• W2924014797 title "Evaluation of the Patient Profile and Current Pattern of Care with Docetaxel Based Adjuvant Regimen in Operable Breast Cancer" @default.
• W2924014797 doi "https://doi.org/10.3329/dmcj.v7i1.40614" @default.
• W2924014797 hasPublicationYear "2019" @default.
• W2924014797 type Work @default.
• W2924014797 sameAs 2924014797 @default.
• W2924014797 citedByCount "0" @default.
• W2924014797 crossrefType "journal-article" @default.
• W2924014797 hasAuthorship W2924014797A5000605562 @default.
• W2924014797 hasAuthorship W2924014797A5043860820 @default.
• W2924014797 hasAuthorship W2924014797A5044433215 @default.
• W2924014797 hasAuthorship W2924014797A5051277841 @default.
• W2924014797 hasAuthorship W2924014797A5068460437 @default.
• W2924014797 hasAuthorship W2924014797A5078578009 @default.
• W2924014797 hasBestOaLocation W29240147971 @default.
• W2924014797 hasConcept C121608353 @default.
• W2924014797 hasConcept C126322002 @default.
• W2924014797 hasConcept C141071460 @default.
• W2924014797 hasConcept C143998085 @default.
• W2924014797 hasConcept C146357865 @default.
• W2924014797 hasConcept C151730666 @default.
• W2924014797 hasConcept C2776608951 @default.
• W2924014797 hasConcept C2777649267 @default.
• W2924014797 hasConcept C2777982462 @default.
• W2924014797 hasConcept C2781190966 @default.
• W2924014797 hasConcept C2781413609 @default.
• W2924014797 hasConcept C530470458 @default.
• W2924014797 hasConcept C71924100 @default.
• W2924014797 hasConcept C86803240 @default.
• W2924014797 hasConceptScore W2924014797C121608353 @default.
• W2924014797 hasConceptScore W2924014797C126322002 @default.
• W2924014797 hasConceptScore W2924014797C141071460 @default.
• W2924014797 hasConceptScore W2924014797C143998085 @default.
• W2924014797 hasConceptScore W2924014797C146357865 @default.
• W2924014797 hasConceptScore W2924014797C151730666 @default.
• W2924014797 hasConceptScore W2924014797C2776608951 @default.
• W2924014797 hasConceptScore W2924014797C2777649267 @default.
• W2924014797 hasConceptScore W2924014797C2777982462 @default.
• W2924014797 hasConceptScore W2924014797C2781190966 @default.
• W2924014797 hasConceptScore W2924014797C2781413609 @default.
• W2924014797 hasConceptScore W2924014797C530470458 @default.
• W2924014797 hasConceptScore W2924014797C71924100 @default.
• W2924014797 hasConceptScore W2924014797C86803240 @default.
• W2924014797 hasIssue "1" @default.
• W2924014797 hasLocation W29240147971 @default.
• W2924014797 hasOpenAccess W2924014797 @default.
• W2924014797 hasPrimaryLocation W29240147971 @default.
• W2924014797 hasRelatedWork W1907119325 @default.
• W2924014797 hasRelatedWork W1985275773 @default.
• W2924014797 hasRelatedWork W2017260812 @default.
• W2924014797 hasRelatedWork W2099928658 @default.
• W2924014797 hasRelatedWork W2171229478 @default.
• W2924014797 hasRelatedWork W2327417211 @default.
• W2924014797 hasRelatedWork W2980453143 @default.
• W2924014797 hasRelatedWork W3030547947 @default.
• W2924014797 hasRelatedWork W3032029751 @default.
• W2924014797 hasRelatedWork W4312019651 @default.
• W2924014797 hasVolume "7" @default.
• W2924014797 isParatext "false" @default.
• W2924014797 isRetracted "false" @default.
• W2924014797 magId "2924014797" @default.
• W2924014797 workType "article" @default.